Neurology Practice Data for Device Sales Teams

Why Neurology Is a High-Value Target for Device Companies

Neurology sits at the intersection of three massive growth markets: neuromodulation devices, specialty pharmaceuticals, and diagnostic imaging. The American Academy of Neurology (AAN) represents over 40,000 members, and the specialty is projected to face a shortage of 19% by 2025 according to the AAN's workforce study. Fewer neurologists treating more patients means each one carries disproportionate purchasing influence.

For device companies, this concentration is both opportunity and challenge. The opportunity: a single neurologist managing 500+ epilepsy patients can generate $2M+ in annual device revenue if they adopt your neuromodulation platform. The challenge: there are only about 20,000 practicing neurologists in the US, and fewer than 4,000 sub-specialize in the areas where most devices are used. You need precise targeting. Every misallocated sales call is expensive.

According to the Bureau of Labor Statistics, the median neurologist salary exceeds $260,000. This is a specialty with significant purchasing authority, particularly in private practice settings where neurologists control their own technology investments.

Neurology Sub-Specialties and What They Buy

Neurology is not one specialty. It's at least six distinct sub-specialties, each with different clinical focuses, different patient populations, and different product needs. The NPI taxonomy code for neurology (2084N0400X) doesn't distinguish between them. Your data has to.

Epileptology (Epilepsy Specialists)

Epileptologists manage patients with seizure disorders, often cases refractory to medication. This is the primary market for implantable neuromodulation devices:

• Vagus Nerve Stimulation (VNS): LivaNova's VNS Therapy system is the market leader. Implanted in patients who don't respond to anti-seizure medications. Average device cost: $20,000-$30,000 per implant.
• Responsive Neurostimulation (RNS): NeuroPace's RNS System detects abnormal brain activity and delivers targeted stimulation. Used in patients who aren't surgical candidates. Higher price point than VNS.
• Electroencephalography (EEG) equipment: Every epilepsy practice needs EEG monitoring capability. Ambulatory EEG, video EEG, and long-term monitoring units represent ongoing equipment and consumable purchases.

There are approximately 1,500-2,000 epileptologists in the US, concentrated in epilepsy centers (often Level 4 centers accredited by the National Association of Epilepsy Centers). Your data needs to identify which neurologists are epilepsy-focused, which centers are accredited, and who the implanting surgeons are (neurosurgeons, not neurologists, perform the actual implantation).

Movement Disorders Specialists

Movement disorders neurologists treat Parkinson's disease, essential tremor, dystonia, and related conditions. This is the primary market for Deep Brain Stimulation (DBS):

• DBS systems: Medtronic, Abbott (St. Jude), and Boston Scientific compete in DBS. Devices cost $35,000-$50,000 per system. The movement disorders neurologist identifies candidates and manages programming. A neurosurgeon implants the device.
• Focused ultrasound: Insightec's Exablate Neuro uses MRI-guided focused ultrasound for tremor. No implant required. Growing competitor to DBS for essential tremor.
• Levodopa delivery devices: AbbVie's Duopa pump and emerging subcutaneous formulations target advanced Parkinson's patients. These are pharma products but require device-like sales approaches because they involve hardware and training.

Roughly 2,000-3,000 neurologists sub-specialize in movement disorders. They cluster in academic medical centers and specialized Parkinson's/movement disorder centers. Unlike epileptologists who may practice independently, movement disorders specialists are more often hospital-employed or part of academic neuroscience departments.

Headache Medicine Specialists

Headache medicine has become one of neurology's highest-value sub-specialties thanks to the CGRP revolution. Aimovig, Ajovy, Emgality, Vyepti, and the gepants (Nurtec, Qulipta) created a multi-billion-dollar market for migraine-specific treatments.

Device opportunities in headache medicine include:

• Non-invasive neuromodulation: Cefaly (supraorbital nerve stimulation), SpringTMS (single-pulse TMS), and gammaCore (vagus nerve stimulation) are FDA-cleared for migraine prevention or treatment.
• Nerve block delivery systems: SphenoCath and similar devices for sphenopalatine ganglion blocks.
• Botox administration: OnabotulinumtoxinA (Botox) for chronic migraine requires regular injections. While Botox is a pharma product, the injection technique and practice workflow create opportunities for injection training tools and practice efficiency products.

Headache medicine specialists number roughly 1,500-2,000. Many are in private neurology practices where they control their own purchasing. They're also scattered across general neurology practices where they see a mix of conditions but have a high concentration of migraine patients.

Neuromuscular Disease Specialists

Neuromuscular neurologists treat ALS, myasthenia gravis, muscular dystrophy, and neuropathies. This sub-specialty is heavily pharma-oriented, with less device opportunity but extremely high per-patient drug spend:

• Gene therapies (Zolgensma for SMA: $2.1M per dose)
• Antisense oligonucleotides (Spinraza for SMA: $750K first year)
• Complement inhibitors (Soliris/Ultomiris for myasthenia gravis: $500K+ annually)
• EMG/nerve conduction study equipment for diagnosis

Neuromuscular specialists are among the most concentrated sub-specialties, with most practicing at academic centers and specialized neuromuscular clinics. There are fewer than 1,500 in the US.

Multiple Sclerosis (MS) Specialists

MS specialists manage patients on high-cost disease-modifying therapies (DMTs). The MS drug market exceeds $25B annually in the US alone. While this is primarily a pharma play, device and diagnostic opportunities exist:

• MRI partnerships: MS monitoring requires regular MRI scans. Practices with in-house or affiliated MRI capability are more valuable accounts.
• Infusion infrastructure: Many MS drugs (Ocrevus, Tysabri, Lemtrada) require infusion. Practices need infusion chairs, pumps, monitoring equipment, and infusion management software.
• Patient monitoring platforms: Digital health tools tracking MS symptoms, relapse frequency, and medication adherence.

MS Centers of Excellence (designated by the Consortium of Multiple Sclerosis Centers) are the highest-value targets. There are roughly 150 recognized MS Centers across the US, and they manage a disproportionate share of MS patients on high-cost therapies. Check our neurology provider data for MS Center identification.

Sleep Neurology

Sleep medicine overlaps with neurology (and pulmonology, and psychiatry). Neurologists with sleep medicine board certification represent a niche but product-rich segment:

• Polysomnography (sleep study) equipment
• Home sleep testing devices
• CPAP/BiPAP alternatives and oral appliance therapy devices
• Narcolepsy medications (another high-cost pharma market)

Academic vs. Community Neurology

This is the most important segmentation for device sales after sub-specialty. Academic and community neurologists buy differently, sell differently, and require different data.

Academic Neurology

Academic neurologists work at university hospitals and teaching medical centers. Characteristics that affect your sales approach:

• Purchasing process: Hospital procurement committees, value analysis committees (VACs), GPO contracts, and formulary reviews. The neurologist may champion your product, but they don't sign the purchase order.
• Data needs: You need the neurologist's name and sub-specialty, but also the department chair, the VAC members, the supply chain director, and the clinical engineering team. Academic sales are enterprise sales.
• KOL status: Academic neurologists publish research, present at conferences, and influence peer adoption. Identifying KOLs through publication volume, speaking engagements, and clinical trial participation is essential for device companies building adoption.
• Trial sites: Academic centers run the clinical trials that generate the evidence supporting your device. Identifying which centers are running trials for competing products tells you where the market is forming.

Community Neurology

Community neurologists practice in private groups or small hospital-affiliated practices outside major academic centers. They see 70%+ of all neurology patients.

• Purchasing process: The neurologist (or a small group of partners) makes technology decisions directly. Shorter sales cycles. Price sensitivity driven by practice P&L rather than hospital budgets.
• Data needs: You need the neurologist, the practice manager, and any billing/coding staff who will handle device reimbursement. Community neurology sales are relationship-driven.
• Procedure volume: Community neurologists performing neuromodulation procedures (TMS, VNS programming, Botox injections) need volume data to justify capital equipment investments. Your data should include patient panel size or procedure volume indicators.
• Referral networks: Community neurologists rely on primary care referrals. Understanding the referral network around a neurology practice helps you identify practices with growing patient volumes.

TMS: The Device Opportunity Crossing All Sub-Specialties

Transcranial Magnetic Stimulation (TMS) deserves special attention because it spans multiple neurology sub-specialties and is expanding beyond neurology into psychiatry.

TMS is FDA-cleared for major depressive disorder (MDD), OCD, smoking cessation, and anxious depression. It's under investigation for PTSD, chronic pain, tinnitus, and various neurological conditions. The TMS device market is expected to exceed $2B by 2028.

For device companies (NeuroStar/Neuronetics, BrainsWay, MagVenture, Magstim), the target list includes:

• Psychiatrists (primary market for depression TMS)
• Neurologists (emerging market for neurological indications)
• Pain management specialists (chronic pain applications)
• Academic research centers (investigational use)

TMS requires significant capital investment ($70,000-$150,000 per device), dedicated treatment space, and trained technicians. The ideal buyer has high patient volume in a relevant diagnosis, physical space for the device, and financial capacity for the investment. Read our TMS therapy CRM marketing guide for more on reaching TMS-relevant providers.

Building Your Neurology Target List

Here's the data architecture for neurology device sales:

1. NPI foundation with sub-specialty enrichment. Pull all neurology taxonomy codes (2084N0400X base, plus sub-specialty codes for epilepsy, neuromuscular, etc.). Then enrich with board certification data, fellowship training, and practice focus indicators from website and publication analysis.
2. Setting classification. Tag each neurologist as academic, community private practice, hospital-employed community, or multi-specialty group. This determines your sales motion and who else you need to contact at the organization.
3. Procedure and diagnosis indicators. CMS claims data reveals which neurologists are performing relevant procedures (TMS administration, EEG interpretation, EMG/NCS, Botox injection) and managing relevant diagnoses. This is the strongest signal of product-market fit.
4. Center of Excellence identification. Map accredited epilepsy centers, MS Centers of Excellence, and Parkinson's Foundation Centers of Excellence. These centers concentrate the highest-value accounts.
5. Decision-maker mapping. In academic settings, map the department chair, division chief, VAC chair, and clinical engineering lead alongside the sub-specialist neurologist. In community settings, identify the practice owner/managing partner and practice manager.
6. KOL identification. Publication volume in PubMed, conference speaking roles, clinical trial PI status, and advisory board participation. KOLs drive device adoption in neurology more than in most specialties because the procedures are complex and peers look to experts for guidance.

For neurology-specific provider data with sub-specialty classification and setting type, explore our medical device data solutions.

Pharma Targeting in Neurology

Neurology pharma sales deserve their own section because the market is unlike any other specialty. Consider the per-patient annual drug costs:

• MS: $80,000-$100,000/year for most DMTs
• SMA: $750,000-$2,100,000 (gene therapy) or $375,000/year (ongoing)
• Migraine (CGRP): $7,000-$12,000/year
• Epilepsy: $500-$30,000/year depending on drug
• Alzheimer's (new anti-amyloid therapies): $26,500/year (Leqembi)

A neurologist managing 200 MS patients represents $16-20M in annual drug spend. A movement disorders neurologist with 100 advanced Parkinson's patients on specialty medications represents $5-10M. These are some of the highest per-provider revenue opportunities in all of medicine.

Pharma targeting in neurology requires prescriber-level data. CMS Medicare Part D data reveals prescribing patterns by drug category. Open Payments data shows which neurologists are receiving speaker fees, consulting payments, and research grants from specific pharma companies. Combining these signals with sub-specialty classification lets your reps walk into each call knowing exactly what the neurologist prescribes and what competitive relationships exist.

Common Data Gaps in Neurology

After building neurology datasets for device and pharma companies, we see these gaps consistently:

• Sub-specialty misclassification. The NPI registry doesn't reliably distinguish epileptologists from general neurologists. A neurologist who completed an epilepsy fellowship 15 years ago but now runs a general neurology practice gets classified the same as one running a Level 4 epilepsy center. Fellowship data alone isn't enough. Current practice focus matters.
• Missing neurosurgeon partners. For implantable devices (DBS, VNS, RNS), the neurologist identifies candidates but a neurosurgeon performs the implantation. Your data needs to map which neurosurgeons work with which neurologists. Missing the neurosurgeon means missing half the decision-making team.
• No Center of Excellence flags. Accredited epilepsy centers, MS Centers of Excellence, and Parkinson's Foundation centers are high-concentration targets that most data vendors don't flag. You have to build this mapping yourself from each organization's directory.
• Academic vs. community mislabeling. A neurologist with an academic title ("Clinical Associate Professor") might practice primarily in a community setting with an adjunct teaching appointment. Practice setting should be determined by where the neurologist sees patients, not by their title.
• Incomplete referral network data. Neurology is heavily referral-dependent. A community neurologist receiving 50 new patient referrals per month is a much better prospect than one receiving 10. Referral volume is hard to measure directly, but practice size, location density, and PCP network proximity serve as useful proxies.

Territory Planning for Neurology Sales

Neurology device territories look different from pharma territories because the target audience is so concentrated. In a typical metro area, there might be 50-100 neurologists but only 5-8 who sub-specialize in the condition your device treats. Territory planning has to account for this concentration:

• Centers of Excellence first. Map every accredited center in your territory. These are your anchor accounts. A single epilepsy center might implant 50+ VNS or RNS devices per year.
• Community high-volume practices second. Identify community neurologists with the procedure volumes and patient panel sizes that justify device adoption. These are your growth accounts.
• Emerging practices third. Newer neurologists building their practices are more receptive to new technology because they haven't established entrenched vendor relationships. They're building their practice identity and are open to differentiation through new devices.

Your territory data should include not just provider counts but estimated procedure volumes, patient panel sizes, and competitive device installations. A territory with 100 neurologists and zero DBS-capable surgeons is a very different sales challenge than one with 100 neurologists and 3 active DBS implanters.